View more job listings or post a job
Revolution Medicines Senior Scientist, DMPK and Clinical Pharmacology
Quintara Discovery Research Scientist (Bioanalysis)
Quintara Discovery Research Scientist (Bioanalysis)
Chinook Therapeutics, Inc Sr. Scientist, In Vivo Pharmacology (Team Lead)
AbVision Senior/Principle Scientist (Immunology/Cell Biology)
Genentech, Inc. Associate Scientist, Biomarker Mass Spectrometry Laboratory  
Genentech, Inc. Senior Scientific Researcher for Biomarker Mass Spectrometry Laboratory
Genentech Inc. Contractor Scientist–Drug Metabolism
Genentech, Inc. Associate Scientist / Scientist, Biotransformation and ADME of New Modality  
Genentech, Inc. Scientist / Sr. Scientist, Drug Metabolism and Pharmacokinetics  
Post a job

Seminar luncheon

Early Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential: A Pharmaceutical Industry Perspective

Speakers: Borje Darpo, MD, PhD, iCardiac Technologies
Date: 2017-02-03
Time: 11:00-13:30 Pacific Time
Registration fee: (CDN): Food: $0.
Location: The Floral Hall at VanDusen Gardens, Oak St. at 37th Ave, Vancouver
Major Sponsor: (1)iCardiac Technologies
Vendor show vendors registered to date: (7)Altasciences; BRI Biopharmaceutical Research Inc.; Cardinal Health; Cellular Dynamics Intl; Eurofins Cerep-Panlabs; WORLDWIDE CLINICAL TRIALS; XenoTech
Registration deadline:2017-02-01  (it will close sooner if the seating cap is reached)

About the Topic

Based on extensive experience with exposure response analysis of ECG data and the IQ-CSRC validation study, ICH 14 has been revised and now allows the thorough QT (TQT) study to be replaced by robust ECG monitoring and exposure-response (ER) analysis of data generated from First-in-Man studies. This seminar will discuss the IQ-CSRC study, requirements for Early QT assessment, share examples of successful TQT study waivers and give an update on recent regulatory discussions on studies using exposure analysis.


Who should attend:

Those working in academia and industry, pharmaceutical research and development, clinical development, regulatory affairs, and drug safety in general.

About the Speakers

Borje Darpo, MD, PhD, Chief Scientific Officer, iCardiac Technologies. Borje Darpo is board-certified in cardiology and internal medicine and Associate Professor of Cardiology at the Karolinska Institute since 2000. He has 11 years of pharma experience, including senior management positions in small, mid-sized and large pharma, as well as from a global CRO. He has led or has been responsible for projects in all phases of clinical development, including filing and approval of an NDA. Dr. Darpo’s experience from cardiovascular safety assessment of drugs is broad and includes participation in the generation of regulatory guidances on QT assessment and CV safety assessment.

┬ęPharmaceutical & BioScience Society, International; Last Modified: 7/5/2020; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Hypha Discovery Ltd. Experts in scalable synthesis & purification of drug metabolites, including CYP, AOX, FMO metabolites as well as O-, N-, acyl glucuronides & sulfates.
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad